Unique product and service portfolio extensively covers all steps from cell line development to commercial manufacturing processes
Sartorius Stedim Biotech (SSB) has developed an innovative and fully integrated technology platform to meet the requirements of today’s upstream bioprocessing.
It combines a top-performing expression system with outstanding equipment and process control for the rapid development and scale-up of robust, high-titre commercial manufacturing processes.
The biopharmaceutical industry is facing a series of challenges that it must address for it to deliver safe and efficacious products to a market made increasingly competitive by the emerge of biosimilar products.
Companies must rapidly assess and then focus their investments on those drug candidates that have the greatest chance of being successful. To do this, they must cut early stage development timelines and increase the speed with which they can reach the clinic.
The upstream technology platform, which combines a range of products and services that SSB has developed, addresses this challenge without compromising on product quality, process productivity or robustness.
Biopharmaceutical manufacturers will be able to reach the clinic in 14 months by leveraging this new platform. The royalty free CHO expression platform of SSB’s subsidiary Cellca delivers the titres required to meet companies’ cost of goods objectives. Cellca can establish a research cell bank for their clients within just 4 months.
The automated ambr15 micro-bioreactor system is capable of controlling 24 or 48 micro-bioreactor experiments. The system accelerates clone selection and scales up with ease to BIOSTAT STR single-use bioreactors, which biomanufacturers have successfully implemented at pilot and GMP production scales.
To reduce early stage development timelines still further, SSB has integrated more than one hundred off-the-shelf and prequalified assays from BioOutsource into its platform, allowing the rapid testing and analysis of biosimilar products.